A message for our valued healthcare professionals:
ArcMesa Educators is very pleased to announce that we are expanding our learning
communities and improving our website so we can offer the most effective and
convenient learning experience for the healthcare professional.
If you are a returning registrant and wish to check your earned credit history
or print certificates for courses you have completed with ArcMesa Educators, we
welcome you back and request that you please
click here to access our
login page. If you are new to
our site, we welcome you to join us and your colleagues who have already
discovered the longest running, fully-accredited provider of CME/CE activities
on the internet -- where we learn, share and teach.
Thank you for making us part of a shared goal to improve patient care and
quality of life!
-The ArcMesa Educators Team
The activities listed below are the most recent activities offered by Arcmesa.org.
For a complete listing of programs available please select a specific "Therapeutic
Area" to the left side of this page, or the "Courses"
link located within the top navigation of the site.
HIV Patients and Weight Loss: Optimizing Care to Improve Outcomes Faculty: Robert Demling, MD - Chair | Donald Kotler, MD | Christine Wanke, MD CME credit hours: 1.0 HIV Patients and Weight Loss: Optimizing Care to Improve Outcomes: HIV-associated
wasting was first identified by the Centers for Disease Control as an AIDS defining
condition in 1987. With the advent of highly active antiretroviral therapy, it was
hoped that control of viral count would result in the elimination of wasting as
a major sequel of HIV infection. This has turned out not to be the case. HIV wasting
remains a serious, debilitating, and sometimes life-threatening condition. Care
providers need to be vigilant to identify and properly treat patients who suffer
from this disorder. This activity will review the pathogenesis of protein energy
malnutrition in general and its relation to the etiology of HIV-related weight loss.
Additionally, we will discuss the epidemiology of HIV-associated wasting and the
treatment options available.
Osteoporosis: Opportunity for Better Outcomes Faculty: Felicia Cosman, MD | Nelson B. Watts, MD | Michael R. McClung, MD | Kenneth W. Lyles, MD CME credit hours: 2.0
Osteoporotic fractures affect millions of postmen-opausal women, and can have a
substantial negative effect on daily functioning and quality of life. These fractures
are associated with an increased risk of future fracture, clinical complications,
and a higher risk of death. However, osteoporosis remains woefully under-diagnosed
and undertreated, even among patients who already have fractures. When treatment
is provided, adherence and persistence are often suboptimal, reducing the likelihood
of a positive outcome.
Congestion in Acute Decompensated Heart Failure: A Case Based Discussion Faculty: Mihai Gheorghiade, MD, FACC | Clyde W. Yancy, MD, FACC, FAHA, FACP CME credit hours: 1.5
This program reviews the definition, demographics, and risks of acute decompensated
heart failure. Our expert faculty will discuss the strengths, limitations and concerns
of standard therapies such as diuretics, vasodilators, inotropes, and natriuretic
peptides. The faculty will also discuss emerging therapies including ultrafiltration,
adenosine antagonists, and vasopressin receptor antagonists. This activity aims
to give cardiologists and other cardiac care givers a good understanding of how
to optimize medical therapy for their patients with acute decompensated heart failure,
with an emphasis on relieving symptoms.
ACS Patients and Antiplatelet
Resistance: Where We Are and Where We're Going. Faculty:Deepak L. Bhatt, MD | Cindy L. Grines, MD | Peter B. Berger, MD CME / CE credit hour: 1.5 Myocardial ischemia secondary to acute restrictions in coronary artery
blood flow leads to acute coronary syndromes (ACS). Dual antiplatelet therapy with
aspirin and clopidogrel is the standard of care for patients with ACS. However,
resistance to these agents is associated with adverse clinical events, and is of
great concern to clinicians. This educational program will review clinical data
pertinent to the current state of antiplatelet therapy for the management of patients
with ACS.
Promoting Metabolic and Endocrine
Health in Children and Adolescents Treated with Antipsychotics Faculty:
Christoph U. Correll, MD |
Robert L. Findling, MD |
Linmarie Sikich, MD CE credit hour: 1.0 Clinicians need to carefully consider the overall impact of weight gain,
associated metabolic issues, and endocrine abnormalities associated with antipsychotic
treatment. Several recent epidemiological studies have documented a sharp
increase in the prescription of second-generation antipsychotics for children and
adolescents with psychotic and non-psychotic conditions. A thorough understanding
of the different adverse effect profiles of second-generation antipsychotic agents
is required to effectively manage the mental and physical health of this vulnerable
patient population.
Generic Substitution and Therapeutic
Equivalence of Antiepileptic Drugs: Clinical and Pharmacoeconomic Issues in Epilepsy
Management A Priority Report Faculty: John M. Pellock, MD | Andrew J. Pultz, Jr, PharmD, RPh CME / CE credit hour: 1.0 The issue of generic drug substitution is complex and often poorly understood
by physicians and pharmacists. Although the FDA requires that two drugs are similar
as demonstrated by bioequivalence data, therapeutic equivalence (or therapeutic
effectiveness) and bioequivalence are not necessarily the same. In the case of antiepileptic
drugs (AEDs), the therapeutic range over which they are effective may be narrow
and, although generic substitution of AEDs may be appropriate for some patients
with epilepsy, it may represent suboptimal care for others. This program will give
an overview of these and other important issues associated with generic substitution
of AEDs.
Translating Evidence to Practice:
A Case-Based Approach to VTE Prevention, Diagnosis & Management Faculty: Samuel Goldhaber, MD, | Ruth B. Morrison, RN, BSN, CVN | James B. Groce, III, PharmD, CACP | Sylvia McKean, MD CME credit hour: 2.0
This case-based educational program will help you to identify and discuss pertinent
clinical data for the treatment and prevention of VTE, as well as demonstrate how
these data can be interpreted and applied into clinical practice. This would include
discussion of current issues and controversies surrounding management of VTE, identifying
risk factors for VTE, the treatment and secondary prophylaxis in VTE, treatment
options for the management of acute PE, as well a special consideration for the
medically ill or patients with comorbidities. By reviewing specific patient cases,
our esteemed faculty will provide concise and contemporary insight addressing concerns
practitioners have regarding the management of patients with VTE.
The Practical and Regulatory Perspective
of Bioequivalence Faculty: Sandra L. Kane-Gill, PharmD, MSC | Joseph F. Dasta, MS, FCCM, FCCP | Nicholas M.
Fleischer, RPh, PhD. | Mary Lea Gora-Harper, PharmD, FASHP CE Credit hour: 1.0
Bioequivalence needs to be determined before an automatic substitution of products
or product dosage forms can be made. When automatic substitutions between
brand and generic, generic and generic or between dosage forms are made, clinicians
need to be aware of the potential clinical and regulatory issues associated with
these substitutions. While product interchange between brand and generic medications,
generic and generic medications or different forms of the same product is not typically
a problem, this activity will highlight some examples of clinical concerns and related
regulation considerations. It will also provide some direction on obtaining
relevant information of bioequivalence.
www.Arcmesa.org is dedicated to helping maintain and improve
quality of life through medical education. All CME / CE activities are created in
accordance with the latest industry policies and guidelines. From live symposia
coverage to print monographs and CD ROMs, all our activities are free and available
online at Arcmesa.org.
All information content within shall be considered confidential property
of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.
ACS Patients and Antiplatelet
Resistance: Where We Are and Where We're Going. 
Promoting Metabolic and Endocrine
Health in Children and Adolescents Treated with Antipsychotics
Generic Substitution and Therapeutic
Equivalence of Antiepileptic Drugs: Clinical and Pharmacoeconomic Issues in Epilepsy
Management
Translating Evidence to Practice:
A Case-Based Approach to VTE Prevention, Diagnosis & Management
The Practical and Regulatory Perspective
of Bioequivalence